

## Special Issue

# Recent Advances in Epithelial Cells in Human Lung Disease

### Message from the Guest Editors

Diverse cells of the airway epithelium play critical roles in response to injury, host defense, and the maintenance of homeostasis in the lung. When compromised, they also significantly contribute to human lung disease. Advances in cell biology over the last decade have yielded human in vitro research platforms derived from airway cells, and the epigenetic profiling of these models has the potential to discover key factors that regulate gene expression alterations in lung disease. Characterizing the role and function of existing and newly discovered epithelial cell populations is essential in order to provide clues to disease pathogenesis and treatment discovery. This Special Issue aims to expand our understanding of complex molecular pathways within the airway epithelium in the pathophysiology of pulmonary diseases such as cystic fibrosis, pulmonary fibrosis, chronic obstructive pulmonary disease, and COVID-19 using personalized disease models and omics technology, as well as explore insights into novel therapeutics and drug delivery strategies.

### Guest Editors

Dr. Irene Oglesby

Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

Dr. Chiara De Santi

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/159004](https://mdpi.com/si/159004)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).